当前位置: 首页 >> 检索结果
4782. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
作者: Bob T Li.;Egbert F Smit.;Yasushi Goto.;Kazuhiko Nakagawa.;Hibiki Udagawa.;Julien Mazières.;Misako Nagasaka.;Lyudmila Bazhenova.;Andreas N Saltos.;Enriqueta Felip.;Jose M Pacheco.;Maurice Pérol.;Luis Paz-Ares.;Kapil Saxena.;Ryota Shiga.;Yingkai Cheng.;Suddhasatta Acharyya.;Patrik Vitazka.;Javad Shahidi.;David Planchard.;Pasi A Jänne.; .
来源: N Engl J Med. 2022年386卷3期241-251页
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conjugate, in patients with HER2-mutant NSCLC have not been investigated extensively.
|